Search SciPol

Brought to you by
November 6, 2017

Sarepta turns to Duke’s CRISPR work for next-gen DMD therapies

  • Industry
  • Genetics/Genomics

FierceBiotech – Sarepta has been signing a series of new R&D pacts since its controversial Duchenne muscular dystrophy (DMD) drug approval last fall, and today it’s penned a deal for one of the hottest research areas around: CRISPR.

In a deal with Duke University (financial terms were not disclosed), Sarepta gains an option for an exclusive license for this form of the gene-editing tech, which comes out of the lab of Charles Gersbach, Ph.D.

Read more at FierceBiotech.

Image Citation